Straits Times Index
3,287.75 -5.38 (-0.16%) S&P 500
5,002.41 -69.22 (-1.36%) Dow
37,884.11 -576.81 (-1.50%) Nasdaq
15,415.30 -297.45 (-1.89%) Bitcoin USD
63,363.09 -2,738.74 (-4.14%) CMC Crypto 200
1,366.26 -16.31 (-1.18%)
West Pharmaceutical Services, Inc. (WST)
| Previous close | 385.73 |
| Open | 384.48 |
| Bid | 376.64 x 800 |
| Ask | 383.59 x 800 |
| Day's range | 364.89 - 385.00 |
| 52-week range | 310.42 - 415.73 |
| Volume | |
| Avg. volume | 540,564 |
| Market cap | 26.954B |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | 46.79 |
| EPS (TTM) | 7.87 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 0.80 (0.21%) |
| Ex-dividend date | 23 Apr 2024 |
| 1y target est | 400.43 |
- GuruFocus.com
West Pharmaceutical Services Inc. (WST) Q1 2024 Earnings: Adjusted EPS Rises Amidst Sales Decline
Company Reaffirms Full-Year Guidance and Raises EPS Outlook
ZacksWest Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates
West Pharmaceutical (WST) delivered earnings and revenue surprises of 20.93% and 3.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Reuters
West Pharma posts beat-and-raise quarter aided by strong demand for injectables
West Pharmaceutical Services on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to manufacture injectable therapies. The company expects sales growth to ramp up as the year progresses, partly due to a surge in demand for components used in the packaging of newer treatments, including Novo Nordisk's diabetes drug Ozempic, weight-loss drug Wegovy, and Eli Lilly's diabetes drug Mounjaro. CEO Eric Green said that he expects a majority of sales growth to take place in the second half, as biotech clients work through their existing inventory.
